Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey

被引：0
|
作者：
Bianchi, Gerolamo [1 ]
Carletto, Antonio [2 ]
Epis, Oscar M. [3 ]
Scioscia, Crescenzio [4 ]
Semeraro, Angelo [5 ]
Donati, Chiara [6 ]
Bazzichi, Laura [7 ]
Lapadula, Giovanni [8 ]
Sinigaglia, Luigi [9 ]
Lo Monaco, Andrea [10 ]
机构：
[1] Osped La Colletta, Div Reumatol, Genoa, Italy
[2] Univ Verona, Rheumatol Unit, I-37100 Verona, Italy
[3] AO Osped Niguarda Ca Granda, Rheumatol Unit, Milan, Italy
[4] Univ Bari Aldo Moro, DIM Sez Reuamtol, Bari, Italy
[5] ASL Taranto, Unita Operat Reumatol, Taranto, Italy
[6] Roche SpA, Monza, Italy
[7] Univ Pisa, Div Reumatol, Pisa, Italy
[8] Univ Bari, DIMIMP Rheumatol Unit, Bari, Italy
[9] IOG Pini, Rheumatol Dept, Milan, Italy
[10] Osped S Anna Ferrara, Ferrara, Italy
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
498
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey
    Bianchi, Gerolamo
    Carletto, Antonio
    Epis, Oscar Massimiliano
    Scioscia, Crescenzio
    Semeraro, Angelo
    Bianchino, Laura
    Bazzichi, Laura
    Lapadula, Giovanni
    Sinigaglia, Luigi
    Lo Monaco, Andrea
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1045 - S1046
  • [2] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Monchablon, Clelia
    Gonde, Henri
    Pouplin, Sophie
    Varin, Remi
    Vittecoq, Olivier
    Lequerre, Thierry
    CLINICAL RHEUMATOLOGY, 2020, 39 (01) : 207 - 216
  • [3] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Clélia Monchablon
    Henri Gondé
    Sophie Pouplin
    Rémi Varin
    Olivier Vittecoq
    Thierry Lequerré
    Clinical Rheumatology, 2020, 39 : 207 - 216
  • [4] RHEUMATOID-ARTHRITIS - DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    KIRWAN, JR
    CURREY, HLF
    CLINICS IN RHEUMATIC DISEASES, 1983, 9 (03): : 581 - 599
  • [5] Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
    Agarwal, S.
    Zaman, T.
    Handa, R.
    SINGAPORE MEDICAL JOURNAL, 2009, 50 (07) : 686 - 692
  • [6] Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Choy, Ernest
    Aletaha, Daniel
    Behrens, Frank
    Finckh, Axel
    Gomez-Reino, Juan
    Gottenberg, Jacques-Eric
    Schuch, Florian
    Rubbert-Roth, Andrea
    RHEUMATOLOGY, 2017, 56 (05) : 689 - 697
  • [7] Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis
    Haibel, H.
    Specker, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2009, 27 (04) : S159 - S163
  • [8] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Xerxes Pundole
    Natalia V. Zamora
    Harish Siddhanamatha
    Heather Lin
    Jean Tayar
    Leung Cheuk Hong
    Liang Li
    Maria E. Suarez-Almazor
    Clinical Rheumatology, 2020, 39 : 787 - 794
  • [9] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Pundole, Xerxes
    Zamora, Natalia V.
    Siddhanamatha, Harish
    Lin, Heather
    Tayar, Jean
    Hong, Leung Cheuk
    Li, Liang
    Suarez-Almazor, Maria E.
    CLINICAL RHEUMATOLOGY, 2020, 39 (03) : 787 - 794
  • [10] Use of disease-modifying anti-rheumatic drugs and cardiovascular events in patients with rheumatoid arthritis
    Kaminski, Matthew
    Shishehbor, Mehdi H.
    Gutierrez, Antonio
    Amini, Mohammad R.
    Coats, Walter
    Moghbelli, Meisam
    Askari, Arman T.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : A370 - A370
12345